TWI681191B - 測量天然殺手細胞活性之方法和診斷套組 - Google Patents

測量天然殺手細胞活性之方法和診斷套組 Download PDF

Info

Publication number
TWI681191B
TWI681191B TW106103526A TW106103526A TWI681191B TW I681191 B TWI681191 B TW I681191B TW 106103526 A TW106103526 A TW 106103526A TW 106103526 A TW106103526 A TW 106103526A TW I681191 B TWI681191 B TW I681191B
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
natural killer
interleukin
cells
Prior art date
Application number
TW106103526A
Other languages
English (en)
Chinese (zh)
Other versions
TW201741670A (zh
Inventor
李在冕
尹柱天
朴商佑
金鍾善
Original Assignee
南韓商Ａｔ基因公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商Ａｔ基因公司 filed Critical 南韓商Ａｔ基因公司
Publication of TW201741670A publication Critical patent/TW201741670A/zh
Application granted granted Critical
Publication of TWI681191B publication Critical patent/TWI681191B/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
TW106103526A 2011-02-14 2012-02-14 測量天然殺手細胞活性之方法和診斷套組 TWI681191B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0012983 2011-02-14
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Publications (2)

Publication Number Publication Date
TW201741670A TW201741670A (zh) 2017-12-01
TWI681191B true TWI681191B (zh) 2020-01-01

Family

ID=46672988

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106103526A TWI681191B (zh) 2011-02-14 2012-02-14 測量天然殺手細胞活性之方法和診斷套組
TW101104742A TWI668445B (zh) 2011-02-14 2012-02-14 測量天然殺手細胞活性之方法和診斷套組

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW101104742A TWI668445B (zh) 2011-02-14 2012-02-14 測量天然殺手細胞活性之方法和診斷套組

Country Status (20)

Country Link
US (2) US11442069B2 (enExample)
EP (1) EP2676139B1 (enExample)
JP (5) JP6629497B2 (enExample)
KR (3) KR20120093002A (enExample)
CN (1) CN103370622B (enExample)
AU (2) AU2012219184A1 (enExample)
BR (1) BR112013020454B1 (enExample)
CA (1) CA2826053C (enExample)
CL (1) CL2013002361A1 (enExample)
DK (1) DK2676139T3 (enExample)
EA (1) EA038959B1 (enExample)
ES (1) ES2797549T3 (enExample)
IL (1) IL227952B (enExample)
MX (1) MX361731B (enExample)
MY (1) MY175351A (enExample)
RU (1) RU2635194C2 (enExample)
SG (1) SG192247A1 (enExample)
TW (2) TWI681191B (enExample)
UA (1) UA120697C2 (enExample)
WO (1) WO2012110878A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2015069187A1 (en) * 2013-11-05 2015-05-14 Agency For Science, Technology And Research Bladder Carcinoma Biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
WO2018151821A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US20220128564A1 (en) * 2019-02-14 2022-04-28 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
EP4021180A4 (en) * 2019-08-29 2023-11-08 Board of Regents, The University of Texas System CELL CRYOPRESERVATION MEDIUM
EP4015526B1 (en) * 2019-09-25 2024-10-30 Leto Laboratories Co., Ltd Recombinant interleukin-15 analog
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN118488963A (zh) * 2021-12-17 2024-08-13 肯特大学 囊泡中生产重组生物分子的序列和方法
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082206A2 (en) 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
US20070110713A1 (en) * 2003-07-21 2007-05-17 Transgene S.A. Novel multifunctional cytokines
US20100136052A1 (en) * 2007-06-27 2010-06-03 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient influenza virus for the expression of heterologous sequences

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89121A (pt) * 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
AU693459B2 (en) * 1993-08-09 1998-07-02 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) * 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のｎｋ細胞株
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
AU2004288231A1 (en) 2003-11-05 2005-05-19 Palingen, Inc. Enhanced B cell cytotoxicity of CDIM binding antibody
KR100565764B1 (ko) * 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
CA2604007A1 (en) * 2005-04-08 2006-10-19 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
AU2007277050A1 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2579768T3 (es) 2007-01-11 2016-08-16 Novo Nordisk A/S Anticuerpos anti-KIR, formulaciones y usos de los mismos
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082206A2 (en) 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
US20070110713A1 (en) * 2003-07-21 2007-05-17 Transgene S.A. Novel multifunctional cytokines
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
US20100136052A1 (en) * 2007-06-27 2010-06-03 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient influenza virus for the expression of heterologous sequences

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Lindgren A et al., "Impaired IFN-γ production after stimulation with bacterial components by natural killer cells from gastric cancer patients", Experimental Cell Research, 317(6):849-858, 2011/01/19
Lindgren A et al., "Impaired IFN-γ production after stimulation with bacterial components by natural killer cells from gastric cancer patients", Experimental Cell Research, 317(6):849-858, 2011/01/19 Parihar R et al., "IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells", The Journal of Clinical Investigation, 110(7):983-992, 2002/10 Puren AJ et al., "Interleukin-18 Enhances Lipopolysaccharide-Induced Interferon-γ Production in Human Whole Blood Cultures", The Journal of Infectious Diseases, 178:1830-1834, 1998 *
Parihar R et al., "IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells", The Journal of Clinical Investigation, 110(7):983-992, 2002/10
Puren AJ et al., "Interleukin-18 Enhances Lipopolysaccharide-Induced Interferon-γ Production in Human Whole Blood Cultures", The Journal of Infectious Diseases, 178:1830-1834, 1998

Also Published As

Publication number Publication date
MY175351A (en) 2020-06-22
WO2012110878A3 (en) 2013-01-31
RU2635194C2 (ru) 2017-11-09
IL227952A0 (en) 2013-09-30
MX361731B (es) 2018-12-14
US20220229070A1 (en) 2022-07-21
KR20120093002A (ko) 2012-08-22
KR20130032410A (ko) 2013-04-01
TW201245718A (en) 2012-11-16
WO2012110878A2 (en) 2012-08-23
JP2022043119A (ja) 2022-03-15
JP6629497B2 (ja) 2020-01-15
ES2797549T3 (es) 2020-12-02
IL227952B (en) 2019-01-31
US20140017713A1 (en) 2014-01-16
US12379384B2 (en) 2025-08-05
EP2676139A2 (en) 2013-12-25
JP2014510517A (ja) 2014-05-01
EA038959B1 (ru) 2021-11-15
JP2017129597A (ja) 2017-07-27
KR101438573B1 (ko) 2014-09-12
EP2676139B1 (en) 2020-05-06
KR101341538B1 (ko) 2013-12-18
BR112013020454A8 (pt) 2022-11-29
AU2017202628A1 (en) 2017-05-11
BR112013020454B1 (pt) 2023-03-21
JP6798922B2 (ja) 2020-12-09
TWI668445B (zh) 2019-08-11
JP2023115006A (ja) 2023-08-18
EP2676139A4 (en) 2014-12-03
NZ710432A (en) 2017-04-28
JP7660605B2 (ja) 2025-04-11
AU2017202628B2 (en) 2019-08-22
BR112013020454A2 (pt) 2016-10-18
RU2013141487A (ru) 2015-03-27
NZ614345A (en) 2015-09-25
DK2676139T3 (da) 2020-06-15
MX2013009380A (es) 2013-12-16
EA201391187A1 (ru) 2013-12-30
AU2012219184A1 (en) 2013-09-05
KR20130136012A (ko) 2013-12-11
CN103370622B (zh) 2018-02-13
TW201741670A (zh) 2017-12-01
CA2826053A1 (en) 2012-08-23
CA2826053C (en) 2021-05-25
CN103370622A (zh) 2013-10-23
US11442069B2 (en) 2022-09-13
JP2019207242A (ja) 2019-12-05
CL2013002361A1 (es) 2014-06-27
SG192247A1 (en) 2013-09-30
UA120697C2 (uk) 2020-01-27

Similar Documents

Publication Publication Date Title
JP7660605B2 (ja) がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
CN109425743A (zh) 检测可溶性fam19a4蛋白的微球双抗体夹心检测方法和试剂盒
Crescioli The role of immunological biomarkers in cardiac rejection
CN104628834B (zh) 一种结核感染t细胞免疫检测抗原及其应用
NZ614345B2 (en) Method and use for measurement of nk cell activity
NZ710432B2 (en) Method and use for measurement of nk cell activity
HK1189273B (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
HK1189273A (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
EP2606361B1 (en) A novel method for diagnosing q-fever using a cellular immunological test
Islam et al. Chemokine and chemokine receptor analysis
CN113785201B (zh) 用于检测镍纹蛋白-β活性的方法
JP2019045215A (ja) ナチュラルキラー細胞活性の測定方法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees